Bonac Corporation announced on May 18^th at 1:30 p.m., the commencement of a joint research project with Fukuoka Prefecture for a novel coronavirus treatment at the Fukuoka Prefectural Government.

 

At the press conference, Fukuoka Governor Ogawa made the following statement:

 

“Bonac is a venture company in Fukuoka Prefecture that possesses core technologies in nucleic acid medicine, which is said to be a promising field in pharmaceuticals, and is working on the development of therapeutic drugs for intractable and viral diseases. The Fukuoka Institute of Health and Environmental Sciences conducts PCR tests for novel coronaviruses on a daily basis and has knowledge of viruses and infectious diseases.”

 

“In the future, Fukuoka Prefecture, the Fukuoka Institute of Health and Environmental Sciences, and Bonac will utilize their respective strengths to jointly work toward the development of a therapeutic drug for the new coronavirus, and today is the first day of the project. If our joint research is successful and a new therapeutic agent is developed, I believe it will contribute to humanity not only in Japan but also in the world.”

 

“I sincerely hope that the results of our joint research will play a role in the future as it is essential for us to have more options for vaccines and therapeutics.”

 

Bonac will continue to promote research and development so that the nucleic acid chemistry technology will become a bridge to drug discovery.

 

The signing of the agreement

After the press conference

Contact:

Corporate Affairs

press@bonac.co.jp

Bonac to Initiate Joint Research with Fukuoka Prefecture on the Development of Treatment for COVID-19